Ras association domain family protein 1A (RASSF1A) is one of the more heavily methylated genes in human cancers. In addition to promoter-specific methylation, RASSF1A polymorphisms have been identified in cancer patients. RASSF1A is a tumor suppressor protein involved in death receptor-dependent apoptosis and it is localized to microtubules. Currently, the biological importance of RASSF1A microtubule localization and the functional consequences of RASSF1A polymorphisms is not understood. In this study, we have investigated both RASSF1A microtubule association and polymorphisms. Loss of RASSF1A microtubule association resulted in the nuclear appearance of RASSF1A and the loss of association with a-, c-and b-tubulin. Moreover, the loss of microtubule localization of RASSF1A resulted in enhanced tumorpromoting potential, as determined by a xenograft transplantation model in nude mice. It is surprising that, several RASSF1A polymorphisms also lost the ability to associate with a-, c-and b-tubulin and lost the ability to prevent tumor formation in a xenograft nude mouse model when compared with wild-type RASSF1A. Our results demonstrate a role for RASSF1A microtubule localization in eliciting its tumor suppressor function. In addition, some RASSF1A polymorphisms lack the tumor suppressor function of RASSF1A and, if present in patients, may be tumorigenic.
Introduction
The appearance of cancer is defined by many changes in the genome. They include nucleotide changes (polymorphisms) possibly leading to point mutations, gene amplifications and deletions, chromosomal translocations and epigenetic changes. Tumor suppressor proteins, such as retinoblastoma protein (pRb), p53, p73 and PTEN are all targets for genetic changes (Lowe et al., 2004) . The ras association domain family protein 1A (RASSF1A) tumor suppressor gene is no exception as it is one of the most heavily methylated genes that is epigentically silenced in human cancers, resulting in the loss of RASSF1A expression (Dammann et al., 2005; van der Weyden and Adams, 2007) . In addition, polymorphisms to RASSF1A exist in some cancers that may lead to loss of RASSF1A function (Agathanggelou et al., 2001) .
The RASSF gene family comprises 10 family members that share the presence of the Ras binding domain (van der Weyden and Adams, 2007; Richter et al., 2009) . Several other RASSF family members have been shown to be downregulated in cancer (such as RASSF2, 4 and 6) (Dammann et al., 2005; van der Weyden and Adams, 2007) , and one may be involved in modulating NFkB (RASSF6) (Allen et al., 2007) . The RASSF1 locus contains two major splice variants (A and C) that arise by multiple promoter usage and alternative splicing. The longer isoform, 1A, consists of 340 amino acids and a unique 119-amino acid amino (N)-terminal region, encoded by exon 1Aa. Epigenetic silencing of RASSF1A does not result in the upregulation of RASSF1C or any other RASSF family members. All RASSF proteins contain a Ras binding domain, but direct association with K-Ras has been only observed for RASSF2, RASSF4 and RASSF5/Nore1 (novel ras effector 1) (Vos et al., 2003a, b; Avruch et al., 2009) .
It is now well established that RASSF1A is a microtubule protein that co-localizes with tubulin and can stabilize microtubules in a paclitaxel (taxol)-like manner. It can associate with a-, g-and b-tubulins Vos et al., 2004) and with microtubule binding proteins, such as microtubule binding protein 1B and the microtubule binding protein 1B homolog C19ORF5/ RASSF1A-binding protein 1 (Liu et al., 2005b; Dallol et al., 2007) . These associations may function to stabilize tubulin and allow microtubules to carry out their role during mitosis to allow sister chromatid segregation. Important to the latter is the role of the microtubules within the spindle complex, the single most important complex underlying chromosomal segregation during cell division (Pihan and Doxsey, 2003) . The microtubule spindle complex is regulated by numerous factors and if not formed properly cell death proceeds to prevent inheritable aneuploidy due to chromosome missegregation.
If inheritable aneuploidy proceeds, it can be detrimental, especially if a genetic change is transferred during chromosomal missegregation. One or more missegregation events can result in malignancy leading to cancer. Therefore, it is imperative that we understand what may indirectly or directly affect the stability of microtubules, especially during mitosis.
RASSF1A, 1C, 5 and 7 have been demonstrated to associate with the microtubular network (Moshnikova et al., 2006 (Moshnikova et al., , 2008 Donninger et al., 2007; Sherwood et al., 2008; Richter et al., 2009) . All have been shown to associate with centrosomal elements and, in the case of RASSF1A, with a-, g and b-tubulins. Several groups have observed mitotic-specific associations of RASS-F1A with g-tubulin within centromeres near the region of the microtubule-organizing center. The microtubuleorganizing center is a region, whereby microtubules emerge and is a site of microtubule nucleation and an abundance of g-tubulin (Moshnikova et al., 2006; Cuschieri et al., 2007; Raynaud-Messina and Merdes, 2007) . RASSF1A localizes to spindle poles and centromeric areas during metaphase and anaphase, most likely in association with g-tubulin. RASSF1A may function to protect the polymerization state of tubulin during mitosis, stabilizing it comparatively to the level of paclitaxel/taxol addition and allowing sister chromatid separation (Rong et al., 2004; Vos et al., 2004; Liu et al., 2005a) . Tubulin depolymerization can be induced by the addition of the M-phase-arresting agent nocodazole. In the presence of RASSF1A, tubulin polymerization is stable and tubulins are acetylated . In the absence of RASSF1A (as found in the mouse embryonic fibroblasts from Rassf1a À/À mice; Liu et al., 2003; Rong et al., 2004) , cells more sensitive to nocodazole-induced depolymerization of microtubule resulting in tubulin de-acetylation and destabilization. Destabilized tubulin results in inadequate formation of mitotic spindles, possible chromosome missegregation, inheritable aneuploidy and cancer.
RASSF1A has been demonstrated to associate with the microtubule binding protein 1B homolog C19ORF5/ RASSF1A-binding protein 1 by yeast two hybrid and direct immunoprecipitation analysis (Song et al., 2005; Liu et al., 2005b; Dallol et al., 2007) . C19ORF5 is expressed in tissues with a cytosolic localization not associated with microtubules (Liu et al., 2005a) , whereas RASSF1A has a cytosolic localized and is associated with microtubules. C19ORF5 is recruited to microtubules upon paclitaxel/taxol treatment or RASSF1A ovexpression (Dallol et al., 2007) suggesting a novel role for C19ORF5 to anchor a-and g-tubulin to the centrosomes during microtubule nucleation and regrowth, most likely in association with RASSF1A. However, RASSF1A does not require C19ORF5 for its localization to microtubules and, C19ORF5 does not seem to protect microtubules from depolymerization upon nocodazole treatment. Therefore, it seems that the RASSF1A-C19ORF5 interaction may be an intriguing link between the microtubules, cell-cycle control and apoptosis. The disruption of this pathway may have a large effect on the process of tumorigenesis.
Several groups have tried to identify the minimal region required for RASSF1A microtubule localization. These reports vary considerably identifying regions important for microtubule localization, such as amino acids 120-185 , amino acids 163-257 containing 28% basic charges (Rong et al., 2004) , amino acids 289-340 (Liu et al., 2003) and amino acids 125-138 and 167-186 (Liu et al., 2005b) . Once RASSF1A loses its microtubule localization it seems to be associated within the nucleus. So far, the only functional consequence of these cellular changes with these RASSF1A deletion mutants is modulation of tubulin depolymerization and stability. In this report, we demonstrate mitotic specific associations of RASSF1A with a-, g-and b-tubulin and detail specific amino acid requirements for the microtubule localization of RASSF1A. Lack of RASSF1A microtubule association results in the loss of tubulin acetylation and complete loss of tumor suppressor properties. Furthermore, polymorphisms to RASSF1A also modulate microtubule association and possible tumor suppressor properties.
Results
RASSF1A microtubule localization required two regions within the primary sequence RASSF1A is a microtubule-associated protein that co-localizes with tubulin ( Figure 1a) . Overexpression of RASSF1A in U2OS cells resulted in a distinct microtubular-like appearance that enveloped the cell (Figure 1a , left panel). It is interesting that RASSF1A staining was also concentrated in the perinuclear area of the cell (Figure 1a , middle panel) and was bundled into distinct structures surrounding the nucleus but not in the nucleus (Figure 1a , right panel). Deletion analysis revealed that both amino (N)-and carboxy (C)-terminal regions of RASSF1A were required for the microtubule localization of RASSF1A (as observed for expression constructs 139-340 and for 1-300). Detailed five-amino acid deletions revealed that the sequences 131 SQAEI and 300 ELHNFL were required for microtubule localization ( Figure 1b) . It is interesting that 131 SQAEI is the ataxia telangeictasia mutated (ATM) phosphorylation site on RASSF1A (Agathanggelou et al., 2001 ) and 300 ELHNFL is just downstream of the site of association with the only known downstream effector of RASSF1A-mediated cell death, the modulator of apoptosis 1 (MOAP-1 at amino acid 311 REEEEHL) (Baksh et al., 2005; Foley et al., 2008) . These results are similar to some of the published observations, which suggest that both N-and C-terminal regions of RASSF1A determine microtubule localization.
Loss of RASSF1A-mediated apoptosis in the presence of the dMT mutant of RASSF1A RASSF1A promotes death receptor-mediated apoptosis modulated by direct associations with tumor necrosis factor a receptor R1 (TNF-R1) and with TNFa-related apoptosis-inducing ligand R1 (TRAIL-R1), but not Fas Baksh et al., 2005, respectively) . In U2OS cells, we have observed a robust stimulus-dependent association of RASSF1A with both TNF-R1 and TRAIL (Figure 2a) . However, unlike the wild type, RASSF1A microtubule-defective mutant (dMT) significantly lost its ability to associate with both TNF-R1 and TRAIL-R1 (Figures 2a and b) , suggesting that microtubule localization is required for death receptor association. Furthermore, in support of our data in Figure 2 , the lack of RASSF1A microtubule localization resulted in (i) a significant loss of its ability to promote RASSF1A-driven cell death, as observed by reduced Annexin V staining (a marker of early-to-mid stages of apoptosis, Figures 3a and b) , (ii) reduced cleavage of poly (ADPribose) polymerase (PARP) from the 126-kDa form to the p85-kDa form (PARP is a target for caspase activity, Figure 3c ) and (iii) in a reduction in the rate of internalization of the TNF-R1 (an event that determines how effectively apoptotic stimuli drives the activation of TNF-R1, Figure 3d ). The effect of RASSF1AdMT on TNF-R1 internalization may suggest that RASSF1A may be an integral component of how TNF-R1 becomes internalized and interacts with signaling components. These observations validate the role of RASSF1A in cell death and the biological importance for RASSF1A to be tethered to microtubules.
The dMT mutant of RASSF1A does not lose its ability to self associate suggesting that it maintains a proper tertiary structure As the microtubule association residues are juxtaposed to the association site for MOAP-1, we investigated MOAP-1 association with wild type and dMT mutant of RASSF1A microtubule localization and polymorphisms M El-Kalla et al RASSF1A. MOAP-1 can associate with both wild type and the dMT mutant of RASSF1A in a time-dependent manner as previously observed (data now shown and Baksh et al., 2005) . Similarly, RASSF1A self association was preserved in the dMT mutant of RASSF1A in a similar way to wild-type self association ( Figure 4a ). This self association is required before RASSF1A recruitment to death receptors (Foley et al., 2008) . These data suggest that the dMT mutant of RASSF1A still maintained a tertiary structure to allow both self and MOAP-1 association, but not death receptor association.
Cell-cycle dependent associations of RASSF1A with a-and g-tubulin Several groups have demonstrated association of RASSF1A with a-, b-and g-tubulin Rong et al., 2004; Vos et al., 2004) . However, a comprehensive analysis of how RASSF1A can associate with tubulin has not been carried out. We proceeded to test the association of RASSF1A with a-and g-tubulin under asynchronous conditions, S-phase arrest (and hydroxyurea treatment) or M-phase arrest ( . Experiments in (a) and (b) were repeated six times and significance was evaluated by Student's t-test (two-tailed) with the indicated P-value (*) o0.001 for the difference between GFP1A WT and GFP. Cyclohexamide is a protein synthesis inhibitor that was used to inhibit survival signals and allow cell death to be observed in the cancer cells used in this study. All fluorescence-activated cell sorting analyses were carried out on GFP-positive cells.
(c) HA-RASSF1A WT or dMT mutant were ectopically expressed in U2OS cells and associated TNFa/cyclohexamide-evoked PARP cleavage (see IB: Anti-PARP) was detected using an anti-PARP antibody to detect the cleaved form of PARP (p85 PARP). Also indicated are expression levels for HA-RASSF1A and anti-Erk1/2 expression as loading controls. (d) Stable cells containing either HA-RASSF1A WT or dMT mutant were generated and stimulated with TNFa for the indicated times and the amount of surface TNF-R1 determined by fluorescence-activated cell sorting analysis as described in Materials and methods. Experiment was repeated five times and significance was evaluated by Student's t-test (two-tailed) with the indicated P-value. Right panel to (d) expression of proteins in the stable U2OS cells.
RASSF1A microtubule localization and polymorphisms M El-Kalla et al associations with RASSF1A was only observed under M-phase arrest with 2-mM nocodazole treatment (compare lanes 1, 3 and 5 of Figure 4b , left and right panels). It is not surprising that the dMT mutant of RASSF1A did not significantly associate with a-and gtubulin (compare lanes 2, 4 and 6 of Figure 4b , left and right panels). To further confirm mitotic specific association of RASSF1A with tubulin, we carried out cell-cycle arrest in S phase with the addition of hydroxyurea overnight followed by release from S-phase arrest by removing the media and adding fresh media for the indicated times after release. RASSF1A associated with g-tubulin at 3 h after release from S-phase arrest, a time when majority of the cells were in M phase (cell-cycle profiles were confirmed by fluorescenceactivated cell sorting analysis, Supplementary Figure 1a) . By 6 h and 9 h after release from hydroxyurea association with g-tubulin was lost. These data suggest that RASSF1A/tubulin association is cell-cycle dependent with specific and robust association during M phase.
RASSF1A regulation of tubulin stability
Several groups have demonstrated that RASSF1A can stabilize microtubules by affecting both their polymerization and acetylation states (as described for b-tubulin). The polymerization of tubulin was affected by the overexpression of RASSF1A or by the specific Figure 4 RASSF1A dMT mutant results in the loss of association a-tubulin and g-tubulin association, but not self association. (a) GFP-RASSF1A was co-transfected with HA tagged RASSF1A WT or dMT proteins in U2OS cells. RASSF1A self association was determined by IP with anti-HA antibodies followed by immunoblotting (IB) with the indicated antibodies. (b) HA tagged RASSF1A WT or dMT proteins were ectopically expressed in U2OS cells followed by immunoprecipitation (IP) with either a gtubulin antibody (left panel) or an a-tubulin antibody (right panel) and recovered proteins were separated by SDS-PAGE and immunoblotted (IB) as indicated. Analysis was carried out using asynchronous/interphase, S-phase ( þ Hydroxyurea) or M-phase ( þ nocodazole) arrested cells. (c) HA-tagged RASSF1A WT or dMT proteins were ectopically expressed in U2OS cells followed by immunoprecipitation (IP) with g-tubulin antibody during interphase (asynchronous cells), S-phase ( þ Hydroxyurea), M-phase arrest ( þ nocodazole) or release from S-phase arrest ( þ Hydroxyurea-release). IP samples were recovered and proteins separated by SDS-PAGE and immunoblotted (IB) as indicated. All samples were run on the same SDS-PAGE gel.
RASSF1A microtubule localization and polymorphisms M El-Kalla et al loss of RASSF1A using siRNA knockdown (Dallol et al., 2007) or in cells from Rassf1a À/À mice (Liu et al., 2003; van der Weyden et al., 2005) . In this study, we specifically addressed whether the loss of microtubule association (as observed for the dMT mutant of RASSF1A) may interfere with the stability of tubulin by modulation of tubulin acetylation. The more atubulin is acetylated the more stable it is. U2OS cells were transfected with the indicated constructs, harvested, lysed in RIPA buffer and western blotted with the indicated antibodies. Paclitaxel (Taxol) treatment of the cells resulted in the stabilization of tubulin, especially in the presence of overexpressed wild-type RASSF1A (Figure 5a, middle panel) . The presence of the microtubule destabilizing agents, nocodazole and colchine, abolished the acetylated state of a-tubulin in cells containing the vector control, the dMT mutant of RASSF1A (Figure 5a , top and bottom panels, respectively) and RASSF1C (Figure 5b, bottom panel) . However, this was not the case in cells overexpressing RASSF1A WT (Figure 5a , middle panel). These data would suggest an important role for the microtubule localization of RASSF1A and the importance of 1A (and not 1C isoform) of the RASSF1 gene family in maintaining tubulin stability by modulating the acetylation status of a-tubulin.
Polymorphisms to RASSF1A functionally have reduced ability to associate with and stabilize microtubules Polymorphisms to RASSF1A have been identified, but are not well characterized. It is currently unknown whether they have an impact on the physiological role for RASSF1A in cell death, microtubule stability and/or its tumor suppressor properties. We have begun to explore the role(s) for three polymorphisms of RASS-F1A: C65R (in close proximity to the C1 domain zinc finger), A133S (part of the ATM phosphorylation site) and E246K (part of the Ras binding domain) (Agathanggelou et al., 2001) (Figure 6a ). Confocal imaging revealed that similar to wild-type RASSF1A, the A133S and E246K polymorphic forms of RASSF1A localized to microtubules with o20% having a nuclear localization (Figure 6b and Supplementary Figure 2a) . Figure 5 RASSF1A has a role in stabilizing tubulin. U2OS cells were ectopically expressed with either vector, HA-tagged RASSF1A (1A) WT or dMT proteins (a) or with RASSF1C (b). Cells were treated with nocodazole and colchine (microtubule destabilization agents) or with taxol (a microtubule stabilizing agent). Following treatment, cell lysates were generated by RIPA lysis, proteins separated by SDS-PAGE and immunoblotted (IB) as indicated. For (a) three separate experiments were carried out and acetylated tubulin/total tubulin ratio quantitated in the right panel. P-value for differences between wild-type RASSF1A and vector control under asynchronous conditions was o0.03; P-values were o0.01 for the differences between wild-type RASSF1A and 1AdMT for the asynchronous or nocodazole-treated conditions. For the right panel of (b) acetylated tubulin/total tubulin ratio was quantitated from three separate experiments. P-value for differences between RASSF1A and RASSF1C under asynchronous conditions was o0.04 and o0.02 for nocodazole treatment. All P-values were determined by Student's t-test analysis.
In contrast, the C65R polymorphic form or the dMT mutant of RASSF1A had 480% of cells revealing a nuclear localization and predominantly did not localize to microtubules (Figure 6b and Supplementary Figure   2a ). Both C65R and A133S significantly lost their ability to associate with both g- (Figure 6c ) and a-tubulin (Figure 6d ), whereas the E246K polymorphisms maintained the ability to associate with both g-and The C1 domain associates with membrane lipids and contains a zinc finger binding motif for protein-protein associations with death receptors (such as TNF-R1) (Foley et al., 2008) . The ATM site is specifically phosphorylated by the DNA damage control kinase, ATM (Hamilton et al., 2009) . The RAS association/binding domain functions to potentially associate with the Ras family of oncogenes. Lastly, the SARAH domain is a protein interaction domain for the Salvador/RASSF1/Hpo pathway that associates with the pro-apoptotic kinase, MST1 (Praskova et al., 2004; Matallanas et al., 2007) . Following treatment with these agents, cell lysates were generated, proteins separated by SDS-PAGE and immunoblotted (IB) as indicated.
RASSF1A microtubule localization and polymorphisms M El-Kalla et al a-tubulin. In addition, both C65R and A133S could not promote tubulin acetylation as efficiently as the E246K or WT RASSF1A (Figure 6e ), confirming the reduced ability of both C65R and A133S to associate with tubulin. The lack of cytoskeletal localization of both the C65R and the dMT mutant of RASSF1A most likely explained why these two constructs lacked association with a-tubulin and the inability to promote acetylation of a-tubulin. However, it is not entirely clear why the A133S polymorphism, which maintained wild-type localization, but lacked the ability to associate with g-and a-tubulin. The A133S polymorphism also promoted a reduced level of tubulin acetylation similar to the C65R polymorphism suggesting that the A133S polymorphism may function to destabilize microtubules, while maintaining a localization similar to wild-type RASSF1A (please see Figure 6f ; quantitation of Figure 6f in Supplementary Figure 2b ). This irregularity prompted us to explore associations with b-tubulin, the other major component of the a/b-tubulin dimers that can form microtubules (Wade, 2009 ). To our surprise (in both U2OS and HCT116 cells), the C65R and E246K associated very weakly with b-tubulin when compared with the A133S mutant and wild-type protein of RASSF1A (Figure 6e ). It is uncertain at this time why the E246K mutant cannot associate with b-tubulin. The A133S mutant of RASSF1A may be a unique mutant that can associate with b-tubulin to possibly interfere with a/b tubulin dimers, interfere with stabilizing tubulin and interfere with the tumor suppressor properties of RASSF1A. Further analysis will be required to investigate this possibility. The dMT mutant of RASS-F1A did not associate with b-tubulin (data not shown). We next explored how RASSF1A polymorphisms may affect the ability to promote cell death. Two key elements seem to govern the initiation of RASSF1A-dependent cell death: the loss of self association (Foley et al., 2008) and the loss of association with 14-3-3 (Ghazaleh et al., 2010) . If left unchecked (by either self associations or associations with 14-3-3), RASSF1A may promote uncontrolled cell death or be involved in abnormal growth-control mechanisms. As suspected, RASSF1A self association was retained in the presence of these mutants (Supplementary Figure 2c) , as well as association with 14-3-3 (Supplementary Figure 2d) , suggesting that these polymorphisms have maintained the proper tertiary structure of RASSF1A in these associations. Furthermore, the C65R polymorphisms lacked the ability to efficiently promote PARP cleavage in the presence of TNFa (Supplementary Figure 2e) , whereas A133S and E246K can efficiently promoter PARP cleavage (data not shown). The loss of association with tubulin is, therefore, a direct loss of proteinprotein interaction not explained by a loss or disturbance of RASSF1A tertiary structure. It is interesting that the dMT mutant of RASSF1A lacked the ability to associate with 14-3-3 (Supplementary Figure 2f) , suggesting that 14-3-3 associations may depend upon tethering to the cytoskeleton in a similar manner to other pro-apoptotic activators, such as Bad (Adachi et al., 2003) .
The tumor suppressor property of RASSF1A is inhibited in the presence of the dMT mutant of RASSF1A and by RASSF1A polymorphisms We next investigated how the dMT mutant and RASSF1A polymorphisms might affect the primary role of RASSF1A in preventing tumor formation. Using a xenograft model in athymic nude mice, HCT116 colon cancer cells (containing the indicated expression constructs) were s.c. injected into the right and left flank of nude mice and the resulting tumors were monitored for 35 days. Cells containing wild-type RASSF1A were effective in significantly reducing tumor burden in these mice when compared with animals injected without RASSF1A (Figure 7a , compare 'HA1A WT' with 'Vector'). However, cells containing the dMT mutant of RASSF1A were not effective at reducing tumor burden and, in addition, contained a large population of tumors that were multi-nodal (Figure 7a ). This suggested that if RASSF1A cannot localize to microtubules it may be ineffective as tumor suppressor protein, and, may actually function as an oncogene promoting the accelerated appearance of tumors.
A similar tumorigenicity assay was carried out for RASSF1A polymorphisms. Surprisingly, the C65R mutant of RASSF1A (localizing predominantly to the nucleus) lost its ability to prevent tumor growth and produced a large population of tumors similar to the dMT mutant of RASSF1A (compare Figure 7a with Figure 7b ). Cells containing the A133S or the E248K mutant of RASSF1A-promoted tumor formation significantly above that found in vector control cells and wild-type RASSF1A suggesting that some tumor suppressor property was lost in the presence of these polymorphisms (Figure 7b ). In addition, we carried out two more controls for cysteine changes within the C1 domain of RASSF1A, a C98A and C101A/C102A change (Supplementary Figure 3a) . C98 is not part of the C1 domain zinc finger of RASSF1A and does not perturb associations with death receptors (Foley et al., 2008) and can effectively inhibit tumor formation (Supplementary Figure 3a) . However, a C101A/C102A change was found within the C1 domain zinc finger of RASSF1A and was found to lack the ability to associate with death receptors (Foley et al., 2008) . It is not surprising that cells containing the C101A/C102A expression construct lacked the ability to promote cell death (Foley et al., 2008) and lacked the ability to inhibit tumor formation in a xenograft model in nude mice (Supplementary Figure 3a) . These results confirm the role for RASSF1A as a tumor suppressor protein and the importance of microtubule localization and association with death receptors and subsequent activation of apoptosis.
All experiments were carried out by transient transfections in HCT116 cells. We can obtain 460% of the cells expressing the indicated construct in HCT116 cells by day 2 and expression can still be detected until day 10 after transfection in tissue culture (Supplementary Figure 3b) . Analysis of HA expression in the tumors formed by day 35 indicated that protein expression was not detected using our anti-HA RASSF1A microtubule localization and polymorphisms M El-Kalla et al antibody. We can observe tumor growth between day 7 and 14 for most of the expression constructs suggesting that expression by day 7-10 can drive the growth profile of the cells towards their respective outcomes after day 10 (a point where protein expression may be low or lost). We realize that the tumor microenvironment is different from isolated tissue culture cells, but we speculate that cells containing possible RASSF1A disease-associated polymorphisms commit to defined growth phenotypes within the first 10 days and this drives the expression of the tumors shown in Figure 7b .
Discussion
RASSF1A is a tumor suppressor protein that is frequently epigenetically inactivated in human cancers.
In this study, we demonstrate microtubule localization Figure 7 Tumor-promoting potential of RASSF1A dMT mutant and RASSF1A polymorphisms. Male athymic nude mice were purchased at 6-8 weeks of age from Taconic Laboratories and used in tumorigenicity experiments. Once tumors were formed (usually about day 7-14), growth was followed until tumors were about 20 mm in size. Tumor volume was calculated on the basis of a spherical appearance using the formula 4/3pr For each expression construct 6-8 animals were injected on both flanks to give 12-16 measures of tumor growth and significance was evaluated by either Student's t-test (two-tailed) for both (a) and (b). P-values for (b) between C65R and WT (o0.003); between E246K and WT (o0.008); and between A133S and WT (o0.01). Experiments in (a) and (b) were conducted at the same time and thus have the same vector control results. All experiments were carried out using cells from transiently transfected HCT116 cells that give 460% transfection efficiencies.
RASSF1A microtubule localization and polymorphisms M El-Kalla et al and amino acid requirements for this localization. Both N-and C-terminal regions are required for RASSF1A microtubule localization as a mutant missing both of these regions showed localization to the nucleus (the dMT mutant of RASSF1A, Figure 1b) . RASSF1A dMT lost its ability to associate with death receptors, tubulin, and lacked the ability to stabilize tubulin acetylation. In addition, there was a significant loss of pro-apoptotic activity with the dMT mutant and a significant increase in tumor burden when cells containing the RASSF1A dMT mutant of RASSF1A were subcutaneously injected into nude mice (Figure 7a ). The stabilizing effect of RASS-F1A is specific and does not seem to be shared with RASSF1C (Figure 5b ). These observations suggest that the microtubule localization of RASSF1A is directly connected to its role as a tumor suppressor protein and a mediator of death receptor-dependent apoptosis.
Numerous tumor suppressor proteins have been observed to interact with microtubule proteins and function to regulate microtubule stabilization, such as BRCA1 (Parvin, 2009) , Adenomatous Polyposis Coli (APC1) (Senda et al., 2005) and others (Fisk et al., 2002; Bhat and Setaluri, 2007) . RASSF1A joins the growing list of tumor suppressor proteins that can modulate microtubule dynamics. In addition, RASSF1A can cooperate with some of these tumor suppressor proteins, such as APC1, to modulate intestinal homeostasis (van der Weyden et al., 2008) . Inactivation of RASSF1A and deletions in the APC1 gene are common in human colorectal cancers and may contribute to chromosomal instability in cancer cells. The effect of RASSF1A on chromosomal segregation is well documented and functions to maintain the polymerized tubular structure of tubulin within mitosis even in the presence of the microtubule depolymerization agent, such as nocodazole (Liu et al., 2003; Dallol et al., 2007) .
We have extensively described how RASSF1A can function as a pro-apoptotic modulator of death receptor signaling (Baksh et al., 2005; Foley et al., 2008; Ghazaleh et al., 2010) . In the present study, we additionally describe how the presence of RASSF1A on microtubules may influence death receptor associations (Figures 2a and b) and endocytosis (Figure 3d) , the stability of a-tubulin ( Figure 5 ) and tumor inhibition (Figure 7a ). All are affected by the loss of microtubule localization supporting a role for RASSF1A as a paclitaxel-like microtubule stabilizer and promoter of cell death. Preliminary data demonstrate that the dMT mutant of RASSF1A promoted a faster rate of migration of cells following wounding when compared with wild-type cells (Supplementary Figure 3c) . This observation is in line with high oncogenic properties of the dMT mutant of RASSF1A and highlights the importance of microtubule localization of RASSF1A in not only preventing tumor formation but, possibly, inhibiting metastasis.
If RASSF1A is not on microtubules it can be localized to the nucleus (Figure 1) . A role of RASSF1A within the nucleus is currently unexplored. We have demonstrated association with p120 E4F , a zinc finger transcription factor that differentially regulates the adenovirus E4F gene in an E1A-dependent manner (Fernandes and Rooney, 1997; Fenton et al., 2004) . In addition, p120 E4F can also associate with p14 ARF , retinoblastoma and p53 (Fajas et al., 2000 (Fajas et al., , 2001 Rizos et al., 2003) linking RASSF1A to other tumor suppressor proteins. The RASSF1A/p120 E4F association was found to enhance G1 cell-cycle arrest and S-phase inhibition and promote the stabilization of cyclins (Fajas et al., 2001; Fenton et al., 2004) . Within the primary sequence of RASSF1A, two potential nuclear export sequences can be found that follow the consensus sequence, LxxxLxxL ( LHNFLRIL (numbers denote amino-acid number within the primary sequence of human RASSF1A). It is interesting that 17/35 (48%) of the leucine residues within the primary sequence are found within the last 100 amino acids. It is uncertain whether these residues function as an nuclear export sequences and it is unknown how RASSF1A enters into the nucleus as it does not seem to have a nuclear localization signal, as determined by the NucPre program at http://www.sbc. su.se/Bmaccallr/nucpred/cgi-bin/single.cgi) (Brameier et al., 2007) .
In this study, we have begun to explore the roles of three cancer associated polymorphisms of RASSF1A: C65R (in close proximity to the C1 domain zinc finger), A133S (part of the ATM phosphorylation site) and E246K (part of the Ras binding domain) (Agathanggelou et al., 2001) . The E246K mutant of RASSF1A mimicked the properties of wild-type RASSF1A. However, the C65R polymorphism was found to localize to the nucleus (Figure 6b ), lacked the ability to associate with tubulin and promote tubulin stability in comparison to the wild-type protein (Figure 6c-e) , lacked the ability to regulate entrance into mitosis and significantly promoted the appearance of tumors in nude mice suggesting oncogenic characteristics (Figure 7b ). It is interesting that the A133S polymorphism was found to localize to microtubules (Figure 6b ), lacked the ability to associate with a-and g-tubulin, but associated with btubulin (Figure 6c-e) , and promoted tumor formation similar to the E246K in an accelerated manner when compared with wild type and vector control cells. A133 is part of the recognition site for the ATM kinase, 131 SQAE, and numerous polymorphisms have been identified within the ATM-phosphorylation site in lung, ovarian and breast cancer patients (Gao et al., 2008; Hamilton et al., 2009) . Recently, it was demonstrated that S131 of the ATM site can be phosphorylated using ionizing radiation and requires phosphorylation of S131 to signal p73, induce cell death and suppress colony formation (Hamilton et al., 2009 ). In our study, it is clear that the A133S change interferes with the tumor suppressor function of RASSF1A ( Figure 7b ). As ATM is involved in DNA damage control, the presence of the A133S and/or the S131F polymorphism may confer resistance to chemotherapy and, thus, an important polymorphism to characterize. We speculate that under specific cellular conditions and/or settings these polymporhisms will behave differently to modulate biology. Our observations are in line with those by Dallol et al.
